Immunisation, Treatment and Controlled Human Hookworm Infection (NCT03702530) | Clinical Trial Compass
CompletedNot Applicable
Immunisation, Treatment and Controlled Human Hookworm Infection
Netherlands23 participantsStarted 2018-12-17
Plain-language summary
24 healthy volunteers will be immunized with three times 50 L3 larvae or placebo followed by treatment with albendazol and subsequently challenged with twice 50 L3 larvae.
Who can participate
Age range
18 Years – 45 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Subject is aged ≥ 18 and ≤ 45 years and in good health.
. Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
. Subject is able to communicate well with the investigator and is available to attend all study visits.
. Subject agrees to refrain from blood donation to Sanquin or for other purposes throughout the study period.
. For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of study.
. Subject agrees to refrain from travel to a hookworm endemic area during the course of the trial.
. Subject has signed informed consent.
Exclusion criteria
. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Difference between egg counts between intervention and placebo group
. Known hypersensitivity to or contra-indications for use of albendazole, including co-medication known to interact with albendazole metabolism (e.g. carbamazepine, phenobarbital, phenytoin, cimetidine, theophylline, dexamethasone).
. Known allergy to amphotericin B or gentamicin.
. For female subjects: positive urine pregnancy test at screening.
. Positive faecal qPCR for hookworm at screening, any known history of hookworm infection or treatment for hookworm infection.
. Being an employee or student of the department of Parasitology of the LUMC.
. Current or past scars, tattoos, or other disruptions of skin integrity at the intended site of larval application.